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Surface-exposed proteins often play an important role in the interaction between pathogenic bacteria and
their host. We isolated a pool of hydrophobic, surface-associated proteins of Streptococcus pneumoniae. The
opsonophagocytic activity of hyperimmune serum raised against this protein fraction was high and species
specific. Moreover, the opsonophagocytic activity was independent of the capsular type and chromosomal
genotype of the pneumococcus. Since the opsonophagocytic activity is presumed to correlate with in vivo
protection, these data indicate that the protein fraction has the potential to elicit species-specific immune
protection with cross-protection against various pneumococcal strains. Individual proteins in the extract were
purified by two-dimensional gel electrophoresis. Antibodies raised against three distinct proteins contributed
to the opsonophagocytic activity of the serum. The proteins were identified by mass spectrometry and N-
terminal amino acid sequencing. Two proteins were the previously characterized pneumococcal surface protein
A and oligopeptide-binding lipoprotein AmiA. The third protein was the recently identified putative proteinase
maturation protein A (PpmA), which showed homology to members of the family of peptidyl-prolyl cis/trans
isomerases. Immunoelectron microscopy demonstrated that PpmA was associated with the pneumococcal
surface. In addition, PpmA was shown to elicit species-specific opsonophagocytic antibodies that were cross-
reactive with various pneumococcal strains. This antibody cross-reactivity was in line with the limited sequence
variation of ppmA. The importance of PpmA in pneumococcal pathogenesis was demonstrated in a mouse
pneumonia model. Pneumococcal ppmA-deficient mutants showed reduced virulence. The properties of PpmA
reported here indicate its potential for inclusion in multicomponent protein vaccines.
Streptococcus pneumoniae is an important human pathogen
which causes meningitis, otitis media, sepsis, and pneumonia.
The precise molecular mechanisms by which the pneumococ-
cus invades and damages host tissues are not fully understood.
For many years, the polysaccharide capsule has been recog-
nized as the major virulence factor and consequently was con-
sidered an important vaccine candidate (for reviews see refer-
ences 5 and 34). The use of a 23-valent vaccine containing
capsular polysaccharides from pneumococci commonly causing
disease has had limited effect in reducing the morbidity and
mortality associated with this organism (1, 16, 19, 41). The
current pneumococcal vaccine strategy focuses on the use of
conjugates, in which a limited number of capsular polysaccha-
rides are linked to a carrier protein. The proteins in the con-
jugate vaccines cause a switch in the immune response to
polysaccharides from T-cell independent to T-cell dependent.
This results in an increase in the antibody response and the
generation of memory T lymphocytes. Conjugate vaccines are
more immunogenic in young children than polysaccharide vac-
cines (15, 18). Although the results of early trials look prom-
ising, the long-term efficacy is uncertain since large-scale vac-
cination may over time lead to a shift in serotype distribution
towards capsular types that are poorly immunogenic or not
included in the vaccine. Such a shift may be enhanced by the
horizontal exchange of capsular genes, as described previously
(8, 22, 23).
Over the past few years, much attention has been focused on
the role of pneumococcal proteins in pathogenesis and protec-
tion. Proteins that are involved in the pathogenesis of infec-
tions by S. pneumoniae are considered interesting components
for future conjugate or multicomponent protein vaccines. The
immunological response against such proteins should provide
protection against colonization and infection with S. pneu-
moniae strains of all capsular polysaccharide types. Immuniza-
tion with pneumolysin (36), pneumococcal surface protein A
(PspA) (33, 45, 53), pneumococcal surface adhesin A (PsaA)
(44), and neuraminidase (28) clearly confers protection in an-
imal models.
The purpose of this study was to identify additional pneu-
mococcal proteins with abilities to elicit protective immune
responses. We isolated a pool of hydrophobic, potentially sur-
face-associated proteins of S. pneumoniae that were able to
elicit cross-reactive, species-specific antibodies with opsonoph-
agocytic activity. At least three distinct proteins contributed to
the in vitro opsonophagocytic activity. Two proteins were the
previously characterized surface proteins PspA and oligopep-
tide-binding protein AmiA. The third protein was identified as
the putative proteinase maturation protein A (PpmA) (35a).
The potential of PpmA to elicit protective immune responses
and its role in the pathogenesis of pneumococcal infection are
discussed.
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Bacterial strains, growth conditions, and growth medium. The pneumococcal
strains used in this study are described in Table 1. Pneumococcal strain FT231
was used for protein purification. Bacteria were grown to logarithmic growth
phase (optical density at 550 nm 0.3) in Todd-Hewitt broth (Difco Laboratories,
Detroit, Mich.) supplemented with 0.5% yeast extract (Difco Laboratories)
(THY broth) at 37°C.
Extraction of surface-associated hydrophobic proteins of S. pneumoniae. Bac-
terial cells were harvested by centrifugation (1,500 3 g, 15 min, room tempera-
ture) and washed three times with an equal volume of phosphate-buffered saline
(PBS, pH 7.5). After the final wash, the bacteria were resuspended in 1/25 the
volume of TE buffer (10 mM Tris-HCl, 1 mM EDTA). The cells were disrupted
by ultrasonic treatment (Branson sonifier 250; Branson Ultrasonics, Danburry,
Conn.). The method for extraction with sulfobetaine 14 (SB14) was adapted from
that of Schouls and colleagues (40). In brief, cell walls, membranes, and other
particulate material were collected by centrifugation at 48,400 3 g for 20 min.
The water-soluble cytoplasmic proteins were removed by washing the bacterial
lysates five times with PBS. Pellets were resuspended in 150 mM NaCl and
centrifuged for 20 min at 48,400 3 g. The pellets were incubated for 2 h at room
temperature with 0.25% N-tetradecyl-N,N-dimethylammonio-1-propanesulfon-
ate (SB14; Serva, Heidelberg, Germany) in the presence of 150 mM NaCl–10
mM MgCl2–10 mM Tris-HCl (pH 8.0) with constant stirring. The hydrophobic,
membrane-associated proteins were recovered as described by Wessel and
Flu¨gge (52). Protein concentrations were determined by the method of Bradford
(13).
Protein gel electrophoresis and staining. One-dimensional sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis was carried out in the Bio-Rad
minigel system with 13% polyacrylamide gels. The samples were dissolved in
sample buffer (10 mM Tris-HCl, 1 mM EDTA, 1% SDS, 10 mM dithiothreitol
[DTT], 10% glycerol, 0.01% bromophenol blue indicator [Merck, Darmstadt,
Germany]), boiled for 5 min, and subjected to electrophoresis (39).
Two-dimensional SDS-polyacrylamide gel electrophoresis includes separation
of proteins by isoelectric point and by molecular weight, respectively. Isoelectric
focusing (pI, 4 to 7) was performed with a Multiphor II electrophoresis unit and
Immobiline DryStrips (Pharmacia Biotech, Uppsala, Sweden) according to the
manufacturer’s recommendations, but as modified by Rabilloud and colleagues
(37). The proteins were separated in the second dimension by gradient (12 to
20%) polyacrylamide gel electrophoresis. Polyacrylamide gels were stained with
Coomassie brilliant blue (CBB) (39).
Hyperimmune rabbit antiserum. Hyperimmune antiserum was raised against
the hydrophobic, surface-associated protein pool and distinct CBB-stained two-
dimensional protein gel spots. Shortly after introduction into a one-dimensional
SDS-polyacrylamide gel, the SB14-extracted protein pool of S. pneumoniae
FT231 was stained with CBB and excised from the gel. The total protein fraction,
as well as the individual protein spots cut from the two-dimensional polyacryl-
amide gel, were washed three times with 0.1 M sodium acetate–96% ethanol,
ground into a fine suspension in 0.5 ml of PBS, and subsequently mixed with 0.5
ml of Freund’s incomplete adjuvant (Pierce, Rockford, Ill.). New Zealand White
rabbits were injected subcutaneously in four or five places. The primary injection
was followed by three booster injections at 4-week intervals.
Indirect immunocytometric assay. Pneumococci were grown to logarithmic
phase in THY broth at 37°C and washed three times in ice-cold PBS. The
bacterial pellet was dissolved in 5% rabbit serum in PBS (107 bacteria in a 20-ml
final volume) and incubated for 15 min at 4°C with shaking. After being washed
twice with ice-cold PBS, the bacteria were incubated for 15 min at 4°C with 20 ml
(1:5 dilution) of fluorescein-conjugated goat anti-rabbit immunoglobulin G (IgG;
Jackson ImmunoResearch Laboratories, West Grove, Pa.) with shaking. Finally,
the bacteria were washed twice with ice-cold PBS and resuspended in 100 ml of
ice-cold fresh paraformaldehyde (0.5%) in PBS. The samples were analyzed in a
FACScan flow cytometer (Becton Dickinson, Mountain View, Calif.).
Phagocytosis assay. Analysis of the opsonophagocytic activity of the sera was
performed as described by Alonso DeVelasco et al. (4) and adapted by Jansen et
al. (24). In our assay, S. pneumoniae was grown to logarithmic phase in THY
broth without heat-inactivated human pooled serum, and the bacteria were not
inactivated. Phagocytosis was defined as the uptake and binding of fluorescein
isothiocyanate-labeled bacteria by human polymorphonuclear cells (PMNs) be-
cause of opsonization with antiserum. The opsonophagocytic activity is defined
as the reciprocal of the serum concentration at which 25% (unless otherwise
stated) of the human PMNs were fluorescent.
Western blot analysis. The proteins separated by one-dimensional (0.5 mg)
and two-dimensional (2.5 mg) SDS-polyacrylamide gel electrophoresis were
transferred to Immobilon-P membranes (Millipore Corporation, Bedford, Mass.)
as described by Sambrook et al. (39). The immunological detection of immobilized
proteins was performed as described elsewhere (35a).
Amino acid sequence analysis. For N-terminal amino acid sequence analysis,
the proteins were separated by two-dimensional SDS-polyacrylamide gel elec-
trophoresis as described above with a few modifications. Recrystallized SDS
(Serva) was used for preparing the electrophoresis buffers, and sodium thiogly-
colate (100 mM) was added to the cathodal buffer compartment. The proteins in
the gel were blotted to a Problot membrane (Applied Biosystems, San Jose,
Calif.) with the Multiphor II system (Pharmacia Biotech) according to the man-
ufacturer’s instructions except that 0.02% b-mercaptoethanol was added to the
blotting buffer. The blots were stained with amido black (Merck). Amino acid
sequence analysis was performed with a model 473A protein sequenator (Ap-
plied Biosystems) as recommended by the manufacturer.
For mass spectrometric analysis, the proteins of interest were purified from the
gel, digested with trypsin, and analyzed by mass spectrometry as described else-
where (35a). With Peptide Search (29), the deduced (partial) amino acid se-
TABLE 1. Bacterial strains used in this study
Species and strain Relevant characteristic(s) Sourcea or reference
S. pneumoniae
FT231 Serotype 19, clinical isolate F. Tenover, CDC, Atlanta, Ga.
D39 Serotype 2, clinical isolate 7
CDC205 Serotype 3, clinical isolate J. Butler, CDC, Atlanta, Ga.
EF3296 Serotype 4, clinical isolate C. Svanborg Eden, University of Go¨teborg, Sweden
ATCC6306 Serotype 6A, clinical isolate American Type Culture Collection
911320 Serotype 6A, clinical isolate Our laboratory
950357 Serotype 9V, clinical isolate Our laboratory
S1003 Serotype 11, clinical isolate Our laboratory
ATCC6314 Serotype 14, clinical isolate American Type Culture Collection
950312 Serotype 14, clinical isolate Our laboratory
S1001 Serotype 15, clinical isolate Our laboratory
800129 Serotype 18C, clinical isolate Our laboratory
19F G Serotype 19F, clinical isolate Our laboratory
ATCC6323 Serotype 23F, clinical isolate American Type Culture Collection
950110 Serotype 23F, clinical isolate Our laboratory
S3003 Serotype 38, clinical isolate Our laboratory
19F K Unencapsulated variant of 19F G Our laboratory
Rx1 Unencapsulated variant of D39 42
P376 Serotype 6A, opaque variant of clinical isolate p303 27
P765 Serotype 6B, transparent variant of clinical isolate p314 26
P62 Serotype 9V, opaque variant of clinical isolate p10 51
R189 ermAM-containing strain 2
MS9 D39, ppmA::ermAM This study
S. bovis 961008 Clinical isolate Our laboratory
E. faecalis ATCC29212 Clinical isolate American Type Culture Collection
a CDC, Centers for Disease Control.
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quences were analyzed for matching sequences in all possible translation prod-
ucts of the December 1998 version of the unfinished pneumococcal genome
released by the Institute for Genomic Research (TIGR; http://www.tigr.org/data
/s_pneumoniae/) to identify the proteins. With the BLAST algorithm (6), puta-
tive pneumococcal proteins were analyzed for similarity to sequences deposited
in the November 1999 version of the nonredundant protein database at the
National Center for Biotechnology Information (Washington, D.C.).
Immunoelectron microscopy. Colonies of S. pneumoniae strain FT231 were
fixed in a mixture of 4% formaldehyde, freshly prepared from paraformaldehyde,
and 0.1% glutaraldehyde in sodium cacodylate buffer, pH 7.4. The bacteria were
embedded in 1.5% low-gelling-temperature agarose (Sigma), and fixation was
continued for a total of 24 h. Small pieces of the agarose-embedded bacteria
were dehydrated in ethanol in a CS Auto apparatus (Reichart, Vienna, Austria)
with a progressive lowering of temperature and embedded in Lowicryl HM20
resin (TAAB, Reading, United Kingdom) at 240°C. Ultrathin sectioning was
performed with an Ultracut E microtome (Reichart). Sections were collected on
gold grids and immunolabeled by incubation with anti-PpmA rabbit serum and
anti-PspA rabbit serum, respectively, diluted 1:200 with buffer A (1% normal
goat serum, 1% bovine serum albumin [Biocell], 0.1% Tween 20 [Sigma] in
Tris-buffered saline [pH 8.2]) for 2 h at room temperature. Control specimens
were incubated with normal rabbit serum and in buffer A without primary
antibody. Sections were washed in five 50-ml droplets of buffer A for 5 min each
and incubated for 3 h at room temperature in goat anti-rabbit IgG antibody
labeled with 5-nm-diameter colloidal gold (Biocell, Cardiff, United Kingdom)
diluted 1:100 with buffer A. Final washing was done twice with buffer A and five
times in distilled water. Sections were stained with uranyl acetate and examined
with a Philips CM12 electron microscope (Philips, Eindhoven, The Netherlands)
operating at 80 kV.
Nucleotide sequence analysis of ppmA. Nucleotide sequencing was performed
on ppmA from the pneumococcal strains D39, CDC205, EF3296, P376, P765,
950357, P62, S1003, 950312, S1001, 800129, FT231, 19F G, 950110, S3003, and
Rx1. Two PCR products of 640 and 643 nucleotides that cover the whole gene
were generated with an overlap of 140 nucleotides. The primers 59-TCTCATG
CTTCGTAAAAATG-39 and 59-AGCAAAATCAGCACCTTCTG-39 were used
to amplify the 59 part of ppmA. The primers 59-CTGAATTGACAGATGAAG
CC-39 and 59-CCTTGTACTATGCGTTTTATTG-39 were used to amplify the 39
part of ppmA. PCR amplification of ppmA was performed in a 100-ml PCR
mixture as described for penicillin-binding protein genotyping (35). The PCR
products were purified by sodium acetate precipitation to remove the unincor-
porated nucleotides and primers (39). Purified templates were sequenced with
the Thermo Sequenase dye terminator cycle sequencing premix kit (Pharmacia
Amersham, Roosendaal, The Netherlands) and 50 pmol of each PCR primer.
Sequencing was performed on the Applied Biosystems Prism 377 (PE Applied
Biosystems, Nieuwerkerk, The Netherlands).
Cloning and insertional inactivation of ppmA. ppmA was amplified from S.
pneumoniae strain D39 genomic DNA by PCR with primers pmpp-FW1 (59-G
TTTGGAATTCGCAAGCAAATCACTCTCC-39), positioned at nucleotides
369 to 340 upstream of the ATG start codon, and pmpp-REV1 (59-CAGTAG
GATCCTTGTACTATGCGTTTTATTG-39), positioned at nucleotides 1073 to
1104 downstream of the ATG start codon. The forward and reverse primers
contain EcoRI and BamHI recognition sequences, respectively. The amplified
EcoRI-BamHI-digested ppmA DNA fragment was cloned into pBluescript KS1
(pMS1) and transformed into Escherichia coli DH5a (39). A ppmA mutant was
constructed by insertion of an erythromycin resistance cassette (ermAM) in the
gene. ermAM was amplified from S. pneumoniae strain R189 genomic DNA with
primers ermAM-FW1 (59-AAAGTTCGAAGCTTAAGTTCAAAACTACTTG
CCC-39) and ermAM-REV1 (59-AAAGCTGCAGTTCGAATGTCTTCTCAC
CTTTAG-39). The amplified ermAM DNA fragment was Csp45I-digested and
cloned into the Csp45I site of ppmA (nucleotide position 64 downstream of the
ATG start codon) of pMS1, forming pMS2. The EcoRI-BamHI-digested pMS2
DNA fragment was used to transform S. pneumoniae D39 as described previously
(54). To confirm that ppmA was inactivated by ermAM, chromosomal DNA was
analyzed by PCR with primers pmpp-FW1 and pmpp-REV1. Expression of
PpmA was assessed by Western blot analysis with PpmA antibodies. The ppmA
mutant MS9 was used in the described experiments.
Mouse pneumonia model. Preparation of the challenge dose and intranasal
challenge of mice were performed as described before (25). Significant differ-
ences in the survival time of mice challenged with the ppmA knockout mutants
and parent strain D39 were determined by the nonparametric Mann-Whitney U
test, with significance set at a value of P of #0.05.
RESULTS
Surface-associated protein fraction of S. pneumoniae is able
to elicit opsonophagocytic activity. Approximately 30 polypep-
tides were isolated by the SB14 extraction procedure in rela-
tively high concentrations, as shown by two-dimensional SDS-
polyacrylamide gel electrophoresis (Fig. 1). Immunocytometric
analysis demonstrated that serum raised against the extracted
proteins recognized components at the surface of pneumococ-
cal cells of the homologous strain FT231 (Fig. 2) and seven
other pneumococcal strains (D39, EF3296, 911320, 950357,
800129, 19F, and 950110) that represent eight clinically impor-
tant serotypes (types 2, 4, 6A, 9V, 14, 18C, 19F, and 23F,
respectively) and display seven distinct genotypes (M. Sluijter,
unpublished data). The in vitro serum opsonophagocytic activ-
ity was high (50/%) when determined with the homologous
pneumococcal strain FT231 (Fig. 3A). In addition, the serum
was invariably opsonophagocytically active against six genotyp-
ically distinct pneumococcal strains (EF3296, ATCC6306,
ATCC6314, FT231, 19F G1.1, and ATCC6323) (M. Sluijter,
FIG. 1. Two-dimensional analysis of SB14-extracted surface-associated pro-
teins from S. pneumoniae strain FT231. The proteins were separated by isoelec-
tric focusing (pI, 4 to 7) and gradient SDS-polyacrylamide gel electrophoresis (10
to 100 kDa) and stained with CBB. Circles mark the proteins recognized by
serum raised against the SB14-extracted proteins. The numbers 1 to 9 refer to the
proteins discussed in the text.
FIG. 2. Indirect immunocytometric analysis demonstrating the presence of
surface-exposed epitopes in the SB14 protein fraction of S. pneumoniae strain
FT231. Y axis, number of pneumococci analyzed; x axis, degree of immunoflu-
orescence. Numbers: 1, bacterial autofluorescence; 2, nonspecific binding of
fluorescein-conjugated goat anti-rabbit IgG; 3, specific binding of serum to com-
ponents at the surface of pneumococci.
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unpublished data) representing serotypes 4, 6A, 14, 19, and
23F and two unencapsulated strains (19F K1.1. and Rx1). In
contrast, a low serum opsonophagocytic activity was found
against two strains of the genetically closely related species
Streptococcus bovis and Enterococcus faecalis (Fig. 4).
PspA, AmiA, and PpmA contribute to serum opsonophago-
cytic activity. Two-dimensional Western blot analysis was per-
formed to identify the proteins that were serologically recog-
nized at the surface of pneumococci and responsible for the
in vitro opsonophagocytic activity. The hyperimmune rabbit
serum recognized nine proteins, designated 1 to 9 (Fig. 1).
Monospecific rabbit sera were raised against the individual
proteins. The monospecific sera raised against proteins 2, 3,
and 4 were able to facilitate phagocytosis of pneumococci with
an opsonophagocytic activity of 0.5/, 0.7/, and 5/%, respectively
(Fig. 3B to D). Protein 2 was analyzed by N-terminal amino
acid sequencing, and proteins 3 and 4 were analyzed by mass
spectrometry. Eighteen of the first 21 amino acids of protein 2
were successfully identified (Table 2). The amino acid se-
quence was identical to that of PspA as published by McDaniel
and colleagues (GenBank accession number AAC62252) (31).
The molecular size of PspA deduced from the two-dimensional
protein gel was approximately 65 kDa and correlates with the
size range of PspA (60 to 200 kDa) (17, 50). Mass spectromet-
ric analysis of protein 3 resulted in three peptides that were
identical to AmiA (GenBank accession number P18791) (Ta-
ble 2) (30). Mass spectrometric analysis of protein 4 resulted in
12 peptides (Table 2) that were part of a hypothetical transla-
tion product present in the TIGR pneumococcal genome en-
coding a protein of 322 amino acids (7,659 to 8,597, contig 33).
The calculated size of this hypothetical protein (35.4 kDa)
correlated with the size of protein 4 (approximately 35 kDa)
deduced from the protein gel. This protein has been described
before and designated putative proteinase maturation protein
A (PpmA) due to its homology to proteinase maturation pro-
teins (PrtM) of lactic acid bacteria (35a).
PpmA is located at the surface of S. pneumoniae. Since the
three proteins PspA, AmiA, and PpmA are able to elicit op-
sonophagocytically active antibodies, they are presumed to be
surface associated. The monospecificity of PpmA rabbit serum
was confirmed by Western blot analysis. PpmA serum recog-
nized a single protein band with the correct molecular size (35
kDa) in whole-cell lysates (Fig. 5). We performed indirect
FIG. 3. Opsonophagocytic activity of hyperimmune rabbit sera raised against
the surface-associated pneumococcal protein fraction (A) and sera raised against
proteins 2 (B), 3 (C), and 4 (D) using the homologous strain FT231. The
percentage of fluorescein isothiocyanate-positive (FITC1) human PMNs was
determined at various serum concentrations. p, preimmune serum; h, hyperim-
mune serum.
FIG. 4. Opsonophagocytic cross-reactivity of hyperimmune rabbit serum
raised against the pneumococcal protein fraction using the heterologous pneu-
mococcal strains EF3296, ATCC 6306, ATCC 6314, FT231, 19F G1.1, ATCC
6323, 19F K1.1, and Rx1, S. bovis strain 961008, and E. faecalis strain ATCC
29212. The serotype of the pneumococcal strains is indicated in parentheses. Y
axis, opsonophagocytic activity, defined as the reciprocal of the serum concen-
tration at which 25% of the human PMNs were fluorescent by phagocytosis of
fluorescein isothiocyanate-labeled bacteria. p, preimmune serum; h, hyperim-
mune serum raised against the surface-associated protein fraction.
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immunoelectron microscopy to identify the subcellular loca-
tion of PpmA. For this purpose, anti-PpmA serum was used.
Rabbit serum raised against PspA and normal rabbit serum
were used as positive and negative controls, respectively. Im-
munoelectron microscopy demonstrated that both PpmA and
PspA antibodies bound to the surface of pneumococci (Fig. 6).
PpmA is able to elicit species-specific opsonophagocytic an-
tibodies that are cross-reactive against various pneumococcal
strains. The PpmA antibodies were shown to facilitate phago-
cytosis of eight genetically distinct pneumococcal strains rep-
resenting serotypes 4, 6A, 9V, 14, 18C, 19F, and 23F. Preim-
mune rabbit serum was only opsonophagocytically active when
the unencapsulated variant of strain 19F was used. The op-
sonophagocytic activity of the PpmA antibodies was very low
when S. bovis and E. faecalis were used (Fig. 7).
ppmA is conserved among pneumococcal strains. DNA se-
quence analysis of ppmA from 16 pneumococcal strains repre-
senting 15 distinct genotypes and 13 serotypes, and including
the seven serotypes that cause most of the infections in young
children, revealed limited genetic variation. The variation in
ppmA was randomly distributed, and most of the point muta-
tions were synonymous. Compared to the TIGR genome se-
quence, we found variability in six nucleotides: A33G (n 5 1),
T81A (n 5 10), T81G (n 5 2), C87T (n 5 1), T114C (n 5 13),
G146A (n 5 15), T339C (n 5 3) and G818A (n 5 1). Except
for G146A and G818A, none of the point mutations resulted in
an amino acid substitution. Mutation G146A results in a
Ser49Asp substitution, and mutation G818A results in a
Ser272Asp substitution.
PpmA plays a role in the pathogenesis of pneumococcal
infections in vivo. A ppmA knockout mutant of strain D39 was
generated by insertion mutagenesis. Interruption of ppmA in
erythromycin-resistant transformants was confirmed by PCR
analysis (data not shown). In addition, absence of PpmA ex-
pression was demonstrated by Western blot analysis (data not
shown). To confirm that the ppmA mutation did not affect the
in vitro growth rate, both the mutant and the parent strain
were grown overnight on blood agar, inoculated into THY
broth, and incubated at 37°C for 8 h. During this period, there
was no significant difference in growth rate between the ppmA-
deficient strain and wild-type D39, as judged from the optical
density of the culture (data not shown). To determine the
effect of inactivation of ppmA on virulence, mice were chal-
lenged via the intranasal route with strain D39 and the ppmA
mutant, respectively. Mice challenged with the ppmA mutant
survived significantly longer than mice challenged with the
parent strain D39 (P 5 0.023); median survival times were 51.5
and 33.0 h, respectively (Fig. 8). These data demonstrate that
pneumococcal ppmA deficiency results in an extended survival
time for mice during infection.
DISCUSSION
Various pneumococcal proteins are displayed on the cell
surface. These proteins have a wide range of functions, includ-
ing adherence to host tissues, binding to specific immune sys-
tem components, protein processing, nutrient acquisition, and
uptake of DNA from the environment. Immunization with
several pneumococcal surface proteins has been shown to
confer protection against pneumococcal infection in animal
models. These include PspA (45), PsaA (44), autolysin (9), and
neuraminidase (28). To identify novel protection-eliciting
pneumococcal proteins, we isolated a pool of SB14-soluble,
potentially surface-associated proteins of S. pneumoniae strain
FT231. This protein fraction was able to induce antibodies that
facilitated phagocytosis in vitro. Phagocytosis is a major de-
fense mechanism against pneumococci, and the induction of
opsonophagocytic antibodies is presumed to correlate with in
vivo protection against S. pneumoniae infection (4). Among the
proteins, at least three surface-associated proteins contributed
to the in vitro opsonophagocytic activity.
The pneumococcal proteins were selected for hydrophobic-
ity, immunogenic characteristics, and the ability to induce op-
sonophagocytic antibodies. One of the proteins was the previ-
ously characterized protein PspA. PspA inhibits complement
activation and is proposed to exert a virulence function by
recruitment of the alternative complement pathway, thereby
reducing the effectiveness of complement receptor-mediated
pathways of clearance (48). In addition, PspA functions as a
lactoferrin-binding protein and is suggested to be involved in
iron uptake and thus to contribute to pneumococcal growth
FIG. 5. Specificity of PpmA rabbit serum. Whole-cell lysates of S. pneu-
moniae strain FT231 were separated by one-dimensional protein gel electro-
phoresis, stained with CBB (lane 1), and analyzed by Western blotting with
PpmA serum (lane 2). The positions of the size markers are indicated (in
kilodaltons).
TABLE 2. Partial amino acid sequences of surface proteins 2, 3,
and 4 identified by amino acid sequence analysisa
Protein Name Start-endpositions Sequence
2 PspA 1–21 EEAPVAXQXKAEKDYDAAVXK
3 AmiA 40–49 1. VYTADPETLD
148–159 2. DYLSGTSTDFST
387–394 3. VAAQLPAY












a It is not possible to distinguish between Ile and Leu, Gln and Lys, or Phe and
oxidized Met by mass spectrometry.
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FIG. 6. Cellular localization of PpmA (B) and PspA (C) demonstrated by immunoelectron microscopy. Normal rabbit serum was used as negative control (A).
Electron-dense immunogold particles are located mainly on the bacterial surface. Magnification, 31,125,000. Bar, 100 nm.
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under iron-limited conditions, i.e., in the human host (21).
Surface exposure of PspA has been demonstrated previously
(32, 46), and this characteristic was confirmed in this study by
immunoelectron microscopy. The immunogenic nature of
PspA observed in this study has also been demonstrated in
previous studies (32). In line with the ability of PspA-specific
antibodies to induce opsonophagocytic activity against strains
expressing distinct capsular types, PspA has shown to possess
immune protective potential (14, 32) with cross-protection (17,
47).
The second protein that induced opsonophagocytic antibod-
ies was AmiA, which is a membrane-bound lipoprotein in S.
pneumoniae (2) and part of the AmiA-AliAB oligopeptide
permease that mediates the uptake of oligopeptides (2, 3).
Since S. pneumoniae is auxotrophic for valine, leucine, argi-
nine, asparagine, histidine, and glutamine, uptake of oligopep-
tides is important from a nutritional point of view (43). So far,
no data are available on the possible protective abilities of this
protein. Our data derived from phagocytosis experiments with
AmiA antibodies are the first indications that AmiA may be
protective against pneumococcal infections. The contribution
of the AmiA-AliAB oligopeptide permease system to pneumo-
coccal virulence is currently under investigation.
The third surface-associated protein which possessed the
ability to induce opsonophagocytic antibodies was PpmA.
PpmA is a recently identified pneumococcal protein with sig-
nificant sequence homology to the proteinase maturation pro-
tein (PrtM) of lactic acid bacteria (Overweg et al., submitted
for publication). Like PrtM from lactic acid bacteria (20),
PpmA contains an N-terminal signal sequence, which serves as
a label for translocation and cell membrane anchoring. In this
study, the surface location of PpmA was confirmed by immu-
noelectron microscopy. The protein was able to induce anti-
bodies in rabbits with opsonophagocytic activity. Although the
affinity of the antibodies is unknown, the higher opsonophago-
cytic activity of PpmA antibodies compared to PspA and AmiA
antibodies indicates the presence of relatively more PpmA
molecules at the surface of the pneumococcus. Importantly,
the opsonophagocytic activity of the PpmA antibodies was
species specific and cross-reactive among heterologous pneu-
mococcal strains. The observed opsonophagocytic activity of
preimmune serum when the unencapsulated pneumococcal
strain 19G K was used might be due to the absence of the
capsule leading to the exposure of epitopes that are recognized
by the preimmune serum. The cross-reactivity of the PpmA
antibodies was in line with the limited sequence variation of
ppmA. Like PrtM, PpmA is suggested to function as a mem-
brane-bound isomerase (35a). PrtM is a trans-acting protein
involved in the processing of precursors of serine protease PrtP
into active enzymes (49) and belongs to the family of peptidyl-
prolyl cis/trans isomerases. These enzymes are thought to assist
in protein folding by catalyzing the cis/trans isomerization of
the peptidyl-prolyl bonds in peptides and proteins (38). How-
FIG. 7. Opsonophagocytic cross-reactivity of the monospecific hyperimmune
sera raised against PpmA using the heterologous pneumococcal strains EF3296,
911320, 950312, FT231, 19F G1.1, 950110, 19F K1.1, and Rx1, S. bovis strain
961008, and E. faecalis strain ATCC 29212. The serotype of the pneumococcal
strains is indicated in parentheses. Y axis, opsonophagocytic activity, defined as
the reciprocal of the serum concentration at which 10% of the human PMNs
were positive by phagocytosis of fluorescein isothiocyanate-labeled bacteria. p,
preimmune serum; h, hyperimmune serum raised against PpmA.
FIG. 8. Intranasal challenge of mice with ppmA-deficient S. pneumoniae.
Groups of 10 mice were challenged with 106 CFU of S. pneumoniae strain D39
(solid circles) and its ppmA-deficient derivative (open circles). The survival time
of each mouse is presented. Bars represent the median survival time for each
group.
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ever, the pneumococcal protein(s) that is activated by PpmA is
currently unknown. The differential expression of PpmA in
phenotypic variants of S. pneumoniae indicates that PpmA may
play a role in the pathogenesis of pneumococcal infections
(35a). In the transparent phenotype that is selected for during
nasopharyngeal colonization, PpmA is more prevalent, and
therefore the protein may be involved in adherence through
maturation of surface components or by the activation of pro-
teases or other secreted proteins. In this study, PpmA was
demonstrated to be involved in virulence. Inactivation of ppmA
significantly reduced the virulence of strain D39 for mice as
judged by survival time after intranasal challenge. However,
the ppmA mutant was not completely avirulent. Like D39 mu-
tants deficient in the production of pneumolysin (12), PspA
(10), NanA (10), and LytA (11) that were also reduced in
virulence, the ppmA mutant was still capable of killing mice in
our animal model. The proposed role of PpmA in speeding up
the folding reactions (cis/trans isomerization of the peptidyl-
prolyl bonds) is consistent with the significant but limited re-
duction in virulence of the mutant strain. The rate of matura-
tion of target proteins is presumed to slow in the absence of
PpmA. This will subsequently result in a reduction but not
elimination of target proteins that are modified in their bio-
logically active configuration. Another explanation for the lim-
ited reduction in virulence of PpmA-deficient mutants might
be the presence of other as yet unknown cis/trans isomerases
that partially substitute for the PpmA activity. We conclude
that PpmA contributes to pneumococcal virulence. Based on
the surface location of PpmA and its ability to elicit protective
species-specific antibodies, we also conclude that PpmA may
be an interesting candidate for inclusion in future multicom-
ponent protein vaccines.
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